Last reviewed · How we verify
Sii Licensed IPV — Competitive Intelligence Brief
phase 3
Infectious Diseases
Biologic
Live · refreshed every 30 min
Target snapshot
Sii Licensed IPV (Sii Licensed IPV) — Serum Institute of India Pvt. Ltd.. IPV vaccine works by stimulating the body's immune system to produce antibodies against the poliovirus.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Sii Licensed IPV TARGET | Sii Licensed IPV | Serum Institute of India Pvt. Ltd. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Sii Licensed IPV CI watch — RSS
- Sii Licensed IPV CI watch — Atom
- Sii Licensed IPV CI watch — JSON
- Sii Licensed IPV alone — RSS
Cite this brief
Drug Landscape (2026). Sii Licensed IPV — Competitive Intelligence Brief. https://druglandscape.com/ci/sii-licensed-ipv. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing